Tesamorelin Will Get Advisory Committee Review For Treatment Of HIV-Drug Side Effect
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck-Serono/Theratechnologies' Egrifta would be a first-in-class product for lipodystrophy, which sponsors say is a $1.3 billion market.
You may also be interested in...
Egrifta Advisory Committee Cancellation Jeopardizes March 29 PDUFA Date
FDA attributes the cancellation to "unexpected delays in the preparation of materials for the meeting."
Egrifta Advisory Committee Cancellation Jeopardizes March 29 PDUFA Date
FDA attributes the cancellation to "unexpected delays in the preparation of materials for the meeting."
GSK Brings HCV Assets Into Its Infectious Diseases R&D Center
Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.